ADA 2019 Standards of Care Emphasize Patient-Centered Care
THURSDAY, Dec. 20, 2018 -- Patient-centered care is emphasized in updated clinical practice recommendations from the American Diabetes Association 2019 Standards of Care, published as a supplement to the January issue of Diabetes Care.
The Standards of Care include new and revised recommendations for the diagnosis and treatment of children and adults with diabetes. The authors also address strategies to prevent or delay type 2 diabetes, therapeutic approaches, and optimal management.
The 2019 Standards of Care include important updates and changes. These updates include personalizing diabetes care, detailing the need for ongoing assessment and shared decision making, guidance for professionals' use of language to communicate about diabetes, and a new treatment algorithm that simplifies insulin treatment plans. In addition, the cardiovascular disease management chapter has been endorsed by the American College of Cardiology and includes information on the use of sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists that have proven cardiovascular benefit for people with type 2 diabetes and diagnosed cardiovascular disease. A new section focusing on technology and diabetes includes new recommendations for insulin delivery systems and automated insulin delivery devices, as well as discussion of telemedicine for increasing access to care.
"The new 2019 Standards of Care emphasize a patient-centered approach that considers the multiple health and life factors of each person living with diabetes," William T. Cefalu, M.D., from the American Diabetes Association, said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: December 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.